Parkinson's Trial NCT07644013
Find predictors of faster decline
- Trial ID
- NCT07644013
- Official Title
- Clinical Features and Natural History of Multiple System Atrophy: A Prospective Multicenter Registry Study in China
- Goal
- Find predictors of faster decline
- Status
- RECRUITING
- Sponsor
- Peking University First Hospital
- Study Type
- OBSERVATIONAL
- Enrollment
- 214 participants
- Conditions
- Multiple System Atrophy, Parkinson's Disease, Atypical Parkinsonism
Summary For Families
The goal is to map how multiple system atrophy develops and changes over time in Chinese patients, to find clinical features tied to faster decline or worse outcomes, and to build a long-term patient group for future tests of biological signs and treatments. The study does this by following people at several hospitals, collecting medical records, regular exams and standard symptom scales, tests of blood pressure and other nervous-system functions, brain imaging, lab tests, and biological samples, with in-person and phone visits at set times; researchers will also compare the form with mainly slowed movement to the form with mainly balance and coordination problems. Adults aged 40 to 75 who meet the 2022 diagnostic rules for probable or established multiple system atrophy can join, and people with Parkinson disease or healthy volunteers may be enrolled for comparison. People with other atypical parkinsonian disorders, clear secondary causes of parkinsonism, major conditions that affect autonomic tests, or who cannot give consent are not eligible.
Locations
- Peking University First Hospital, Beijing, Beijing Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to map how multiple system atrophy develops and changes over time in Chinese patients, to find clinical features tied to faster decline or worse outcomes, and to build a long-term patient group for future tests of biological signs and treatments. The study does this by following people at several hospitals, collecting medical records, regular exams and standard symptom scales, tests of blood pressure and other nervous-system functions, brain imaging, lab tests, and biological samples, with in-person and phone visits at set times; researchers will also compare the form with mainly slowed movement to the form with mainly balance and coordination problems. Adults aged 40 to 75 who meet the 2022 diagnostic rules for probable or established multiple system atrophy can join, and people with Parkinson disease or healthy volunteers may be enrolled for comparison. People with other atypical parkinsonian disorders, clear secondary causes of parkinsonism, major conditions that affect autonomic tests, or who cannot give consent are not eligible.
- Who can participate?
- Participants must be between 40 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years and 7 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.